Obermatt
See Similar Stocks →

Procter & Gamble Health

NSI:PGHL · INE199A01012
PharmaceuticalsSmall

360

72
Medium confidence — indicative
Profit price30
Owner Earnings Yield61
Dividend Yield1
Price/Sales41
EV / Gross Profit22
Price/Book8
Return on Capital100
Cash Return on Capital98
Return on Equity96
EBIT Margin93
Gross Profitability100
Cash Conversion40
Owner Earnings Margin81
Sales growth65
Profit Growth61
Long-Term EPS Growth42
Reinvestment19
Price momentum55
Debt load73
Refinancing78
Debt Payback100
Liquidity100
Analyst ratings100
Opinion Changes50
Price Target Upside20
Market mood47
Value Creation13/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Procter & Gamble Health clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Based on 3/5 components.

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeBSE
Founded1967
Employees0
Websitepghealthindia.com
ISININE199A01012
Last UpdateApr 2, 2026
Index & Theme
Nutraceutical

Description

Procter & Gamble Health Limited engages in the manufacture and marketing of pharmaceuticals and chemical products in India and internationally. Business Segments The company has identified its primary reportable segment as Pharmaceuticals. This seg…

Analysis

Quality compounder

Procter & Gamble Health Limited earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess. Worth noting: the cash the business generates has lagged behind what the income statement shows.

On valuation, the picture is expensive. The owner-earnings multiple stands at 28.2×; owner earnings: the cash an owner could take out each year.

Growth is moderate; the safety picture is sturdy. The company scores 13/20 on our value-creation score: creating some value.

Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
45
2023202420252026

All-time high

53

Jan 2024

All-time low

17

Mar 2026

Average rank

34

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
41
27
34
24
Price/Earnings
14
34
49
36
Price/Book
8
14
14
20
Dividend Yield
1
1
71
64
Value (overall)
6
7
43
37

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Procter & Gamble Health with its peers
Procter & Gamble
NYQ:PG
52
CountryUSA
IndustryHousehold Products
SizeXX-Large
Full Stock Analysis →
Supernus Pharma
NMQ:SUPN
81
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Pfizer Limited
NSI:PFIZER
65
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Corcept Therapeutics
NAQ:CORT
20
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Vericel
NMQ:VCEL
82
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Oramed Pharmaceuticals
NAQ:ORMP
47
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →